Advertisement
Organisation › Details
Lytix Biopharma AS
Lytix Biopharma’s technology is based on nature’s own defense mechanisms. The membranes of cancer cells are destroyed. Our unique technology is a new class of cancer immunotherapy that activates the patient`s own immune system. Lytix Biopharma’s strategy is to develop its drug candidates to end Phase II, and then collaborate with partners for the final stages of product development and commercialization. *
Start | 2013-11-28 existent | |
Industry | cancer immunotherapy (immuno-oncology, I-O) | |
Industry 2 | LTX-315 (Lytix Biopharma) | |
Person | Wickholm, Håkan (Lytix Biopharma AS 201603– CEO) | |
Person 2 | Furuseth, Torbjørn (Targovax 201809– CFO before Lytix Biopharma + Aker Biomarine + Trygg Pharma + McKinsey) | |
Region | Tromsø | |
Country | Norway | |
City | 2994 Tromsø | |
Tel | +47-77-675500 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Lytix Biopharma AS
- [1] Lytix Biopharma AS. (9/12/19). "Press Release: Lytix Biopharma AS Appoints Øystein Rekdal as the new CEO"....
- [2] Targovax ASA. (9/13/18). "Press Release: Targovax Strengthens Management Team With the Appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO". Oslo....
- [3] Redx Pharma plc. (1/22/18). "Press Release: Redx Pharma Appoints Chief Medical Officer Who Will Oversee Launch of Phase I Clinical Trial of New Cancer Drug"....
- [4] Lytix Biopharma AS. (8/22/17). "Press Release: Norwegian Cancer Society Invests in Lytix Biopharma AS"....
- [5] Lytix Biopharma AS. (8/21/17). "Press Release: Lytix Strengthens the Board with Clinical Development and Commercial Oncology Experience"....
- [6] Lytix Biopharma AS. (4/21/17). "Press Release: Lytix Biopharma Completes 1st Combination Cohort of LTX-315 and Pembrolizumab in TNBC"....
- [7] Lytix Biopharma AS. (4/20/17). "Press Release: Lytix Biopharma Raises in Total 80 Million NOK"....
- [8] Lytix Biopharma AS. (1/13/17). "Press Release: Lytix Biopharma Announces the Appointment of Torbjørn Furuseth as CFO"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top